| |
3-year bDFS (%)
| |
|---|
|
Criterion
|
Yes
|
No
|
p-value
|
|---|
|
Presurgical PSA ≥10
|
58.2
|
48.2
|
0.8
|
|
Gleason score ≥8
|
40.3
|
65.2
|
0.2
|
|
High grade (≥4)
|
52.2
|
87.5
|
0.3
|
|
pT3
|
46.9
|
69.2
|
0.08
|
|
pT3b
|
41.7
|
60.7
|
0.2
|
|
Positive margin(s)
|
47.7
|
61.4
|
0.3
|
|
≥3 positive margins
|
58.3
|
58.8
|
0.7
|
|
Perineural invasion
|
48.3
|
83.3
|
0.8
|
|
PSA DT ≤12 months
|
58.8
|
51.9
|
0.8
|
|
No PSA negativity
|
48.6
|
58.2
|
0.2
|
|
PreRT PSA ≥2 ng/ml
|
33
|
60.9
|
0.04
|
|
PreRT PSA ≥1 ng/ml
|
30.1
|
68.3
|
0.001
|
|
Surgery-RT interval (≤12 months)
|
36.6
|
54.8
|
0.4
|
|
RT duration (≥60 days)
|
54
|
57.5
|
1.0
|
|
Classical 2D RT
|
70
|
45.7
|
0.2
|
- PSA: Prostate specific antigen; DT: doubling time; RT: radiotherapy.
